Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes is a fully integrated biotechnology company with promising research and development focused on addressing unmet medical needs in therapeutic areas. The company's strong stable of marketed drugs, including Aritstada and Vivitrol, and its profitable base business are expected to generate over $300M in adj. EBITDA this year. Additionally, with ALKS 2680, an OX2R agonist, in Ph 2b studies for NT1/NT2/IH, the company has the potential to grow to over $2B by 2030 in the US, resulting in a positive outlook on the stock.

Bears say

Alkermes is facing positive updates and strong competition in the market for its products, specifically in the sleep disorders market. However, with increased patient numbers and incorporation of a parallel design, their Ph 2 program continues to experience delays which may impact their ability to reach their desired market share and achieve long-term success.

Alkermes (ALKS) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 15 analysts, Alkermes (ALKS) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.